Michael McMillan Charged as DOJ Expands National Health Care Fraud Takedown in 2026

Prosecutors accuse the Las Vegas businessman of serving as a distribution middleman whose reimbursement-driven arrangements allegedly moved government-funded wound-care products, provider profits, sales commissions, and illegal kickbacks through a sprawling nationwide commercial network.

WASHINGTON, DC — Michael McMillan, the 55-year-old owner of Protectus LLC and related businesses, has been charged in North Texas as federal prosecutors broaden their 2026 health care fraud offensive beyond treating clinicians and directly into the distribution networks supplying expensive wound-care products.

The nine-count indictment accuses McMillan of health care fraud, offering and paying unlawful health care kickbacks, and completing seven monetary transactions involving property allegedly derived from criminal activity during a scheme prosecutors describe as running from May 2019 to February 2026.

Federal authorities allege that Medicare, TRICARE, and CHAMPVA paid about $268 million on skin-substitute claims connected to the challenged arrangements, while Protectus allegedly received about $174 million and investigators seized assets worth about $35 million.

Those assertions remain accusations contained in a charging document; McMillan is presumed innocent throughout the proceeding, and prosecutors must establish every element of every offense beyond a reasonable doubt before any criminal responsibility or forfeiture can become final.

The Middleman Moves into the Prosecutorial Spotlight

Health care fraud cases often place a physician, clinic owner, pharmacist, or billing operator at the center of the narrative, but McMillan’s prosecution highlights the government’s increasing interest in commercial intermediaries that can influence choices across numerous unrelated medical practices.

Prosecutors portray Protectus as more than a conventional wholesaler that simply purchased products and resold them at established prices; instead, they describe an organizing platform that allegedly connected products, provider recruitment, claim preparation, reimbursement outcomes, commissions, and post-payment invoicing.

That distributor-focused theory matters because a middleman can potentially magnify questionable incentives across a much larger geographic footprint than one clinic, particularly when sales representatives repeatedly introduce the same financial model to physicians, podiatrists, nurse practitioners, and mobile wound-care businesses.

The word middleman is descriptive rather than a criminal classification, however, and McMillan’s legal exposure depends upon what prosecutors can prove about his knowledge, intent, communications, agreements, payment practices, and connection to allegedly false claims rather than his position within the supply chain.

How the Alleged Protectus Arrangement Worked

According to prosecutors, Protectus offered skin-substitute products without requiring participating medical providers to pay the full purchase price before treatment, thereby reducing the ordinary financial risk a practice might face when acquiring exceptionally expensive material before an insurer decides whether to reimburse a claim.

The indictment alleges that providers generally owed Protectus nothing when a government program denied reimbursement, a feature that purportedly insulated participating practices from a failed claim while leaving the distributor dependent upon successful billing for its own compensation.

When a claim was paid, prosecutors say Protectus typically invoiced the provider for approximately 60 percent to 70 percent of the government reimbursement, rather than using a fixed acquisition price unrelated to the amount approved by the federal benefit program.

That formula allegedly permitted the provider to keep the remaining 30 percent to 40 percent, creating what the government describes as a dependable profit of thousands of dollars for each successful skin-substitute claim and a powerful reason to favor products supplied through McMillan’s companies.

Prosecutors contend that the economic substance of this arrangement constituted remuneration for ordering federally reimbursed products, even though the payments and retained margins were allegedly presented through commercial language associated with discounts, rebates, invoices, and ordinary product distribution.

Following the Money Through the Network

The indictment alleges that government programs paid approximately $268 million for claims associated with the model, including payments from Medicare, the military’s TRICARE program, and CHAMPVA, which supports certain spouses, dependents, survivors, and caregivers connected to qualifying veterans.

Within that total, prosecutors claim Protectus received approximately $174 million, participating medical providers received approximately $94 million in alleged kickbacks, and sales representatives received about $27 million for recruiting providers and generating business tied to successful program reimbursements.

Those numbers should not be added together as separate losses, because the alleged provider share and representative commissions describe money moving within or from the broader reimbursement stream, rather than independent federal payments automatically increasing the government’s asserted total beyond $268 million.

Bank statements, claims data, invoices, distributor contracts, commission schedules, internal messages, provider testimony, and product shipping records will therefore be essential to determine whether the money followed a legitimate commercial structure or an intentionally concealed inducement system.

Why Skin Substitutes Attracted Federal Attention

Skin substitutes can serve a legitimate and valuable clinical role for selected chronic wounds that have not responded to conservative treatment, particularly when a qualified practitioner documents wound measurements, eligibility criteria, prior care, product application, discarded material, and continuing progress.

Yet reimbursement for certain high-cost products can reach extraordinary levels because payment may depend upon the product selected and the quantity applied, producing large financial spreads when providers obtain material below the amount ultimately paid by a government program.

That environment does not automatically make an expensive product, a profitable treatment, or an unusual provider fraudulent, but it gives investigators data that can reveal abrupt billing growth, repeated high-cost applications, concentrated supplier relationships, and margins that appear disconnected from ordinary purchasing risk.

In McMillan’s case, the government is using the reimbursement structure itself as evidence of alleged inducement, arguing that a provider who risked no payment after denial but kept a large share after approval received something economically valuable for ordering through Protectus.

When Discounts Become an Anti-Kickback Issue

Federal law does not prohibit every manufacturer rebate, distributor discount, credit arrangement, free replacement, or volume-based price reduction, and carefully structured commercial terms can operate lawfully when documentation, disclosure, valuation, and statutory or regulatory requirements are properly satisfied.

The criminal question becomes whether something of value was knowingly and willfully offered or paid to induce or reward the ordering, purchasing, recommending, or arranging of an item or service for which a federal health care program may provide reimbursement.

Prosecutors allege that Protectus used the appearance of discounts and rebates to conceal a reimbursement split, while McMillan can challenge whether the pricing was commercially legitimate, sufficiently disclosed, protected by applicable rules, or misunderstood through uncertain billing guidance.

Even an arrangement outside a regulatory safe harbor is not automatically criminal, because prosecutors still must prove the required unlawful intent, and the defense may distinguish aggressive pricing from a knowing agreement to corrupt federally reimbursed medical decisions.

Acquisition Cost and Claim Accuracy

The government also alleges that claims misrepresented providers’ true acquisition costs, a theory that matters whenever the invoice shown during billing does not reflect rebates, credits, contingent obligations, post-payment adjustments, or other terms that reduce what a practice ultimately pays.

From the prosecution’s perspective, a claim can present a materially false financial picture when the program sees one stated price, but the provider privately expects to surrender only part of the reimbursement and retain the balance without bearing ordinary collection risk.

McMillan’s defense may examine whether the relevant forms clearly demanded the information prosecutors now emphasize, whether independent providers or billers controlled each submission, and whether Protectus personnel knew particular entries were inaccurate when the claims reached government programs.

Because broad totals cannot independently prove individual falsity, the parties may contest representative claim sampling, product-by-product pricing, billing instructions, provider knowledge, disclosure practices, and whether any alleged misstatement actually influenced a program’s decision to authorize payment.

Nine Charges Carrying Substantial Consequences

The first count charges health care fraud, requiring proof that McMillan knowingly and willfully executed or attempted to execute a scheme intended to defraud a health care benefit program or obtain its money through materially false or fraudulent representations.

The second count alleges the offer and payment of illegal remuneration under the federal Anti-Kickback Statute, placing the purpose of the financial arrangements at the center of a dispute over discounts, retained reimbursement, provider choices, and sales-driven expansion.

The remaining seven counts allege monetary transactions involving criminally derived property worth more than $10,000, allowing prosecutors to identify discrete financial movements that they contend involved proceeds traceable to the underlying health care fraud or kickback offenses.

Each charged offense can carry significant imprisonment and financial consequences following conviction, although statutory maximum penalties neither predict a sentence nor permit simple multiplication without considering guidelines, proven loss, criminal history, role, restitution, forfeiture, and numerous individualized factors.

The indictment was filed in the Dallas Division of the Northern District of Texas as case number 3:26-cr-00310, and Assistant United States Attorneys Marty Basu and Chad Meacham were publicly identified as the prosecutors assigned to the matter.

A National Takedown Reaching Beyond Medical Offices

McMillan’s prosecution was announced through the Justice Department’s 2026 National Health Care Fraud Takedown, a coordinated initiative charging 455 defendants, including 90 doctors and other licensed professionals, in alleged schemes collectively involving more than $6.5 billion in false claims.

The enforcement action covered 56 federal districts and 45 states and territories, enlisted all 50-state Medicaid Fraud Control Units, and paired criminal prosecutions with civil settlements, provider exclusions, payment suspensions, billing revocations, controlled-substance actions, and international arrests.

Authorities also reported seizing more than $182 million in cash, luxury vehicles, jewelry, and other property nationwide, demonstrating that contemporary takedowns seek to preserve allegedly traceable wealth at the opening of a case rather than waiting until conviction and sentencing.

The McMillan case fits the department’s announced pursuit of accountability from medical offices to corporate leadership, because its central defendant is not accused of personally applying grafts but of allegedly designing and operating the commercial system that encouraged their federally reimbursed use.

By targeting an upstream distributor, the government signals that enforcement exposure can extend to executives, sales managers, marketers, consultants, and financial intermediaries whenever prosecutors believe their compensation structures knowingly shape downstream claims or medical purchasing decisions.

North Texas Becomes a Major Enforcement Hub

Federal officials announced 13 North Texas defendants across seven cases involving more than $365 million in challenged billing, with allegations spanning laboratory testing, brain-wave testing, hospice services, magnetic stimulation, COVID-19 kits, durable medical equipment, and wound-care products.

An independent NBC 5 Dallas-Fort Worth report on the regional enforcement action placed McMillan’s case within that wider crackdown and described seizures that included cash, luxury property, vehicles, jewelry, and other high-value assets.

The regional collection shows why national enforcement announcements are more than one enormous case: investigators can coordinate unrelated prosecutions with common themes while allowing separate judges, juries, evidence records, defendants, and defense strategies to determine each outcome.

McMillan’s approximately $268 million payment figure represents the largest publicly identified amount among the North Texas matters, making his prosecution central to the district’s announcement even as every accompanying defendant remains entitled to an independent presumption of innocence.

Data Analytics Reshape Health Care Investigations

Modern investigators can examine millions of claims for product codes, beneficiary histories, treatment frequency, reimbursement amounts, provider locations, supplier concentration, and sudden growth, allowing unusual patterns to emerge before interviews or subpoenas explain the people and decisions behind those numbers.

For a distributor investigation, analysts can map which practices began using a product after contact with particular representatives, compare billing before and after recruitment, identify recurring percentage margins, and trace whether commissions rose in direct relationship to federal program payments.

Data can powerfully direct an investigation, but an outlier is not a verdict, because legitimate specialization, difficult patient populations, new clinical techniques, regional referral patterns, or rapid lawful expansion can also create statistical results that appear unusual beside broader averages.

The prosecution must therefore connect analytics with human evidence showing knowledge and purpose, while the defense can use complete communications, expert testimony, alternative benchmarks, clinical records, and industry practice to argue that suspicious-looking patterns have lawful explanations.

The Approximately $35 Million Asset Fight

Authorities say property valued at approximately $35 million was seized in connection with McMillan’s case, and the indictment seeks forfeiture of assets allegedly traceable to fraud, kickbacks, or transactions involving criminally derived proceeds if the government ultimately prevails.

Pretrial seizure can prevent disputed property from being transferred, hidden, or depleted while litigation continues, but it does not establish guilt or guarantee that the government can permanently keep every account, investment, vehicle, or parcel initially restrained.

The defense may challenge probable cause, ownership, tracing methodology, valuation, substitute-asset theories, and whether particular funds were commingled with legitimate revenue, while innocent third parties can sometimes assert legally recognized interests through separate forfeiture procedures.

Financial litigation may consequently run beside the criminal case for months or years, requiring detailed reconstruction of incoming reimbursements, ordinary business expenses, taxes, distributions, investments, and purchases before a court determines which assets are legally connected to proven offenses.

Compliance Warnings for the Wound-Care Industry

Distributors should ensure provider pricing is based on documented commercial logic rather than a promised share of reimbursement, especially when a practice bears no downside after denial yet keeps an unusually large margin whenever a government program approves payment.

Providers should independently verify medical necessity, coverage requirements, product quantity, acquisition cost, discount treatment, documentation accuracy, and financial disclosures instead of assuming that a distributor’s billing support transfers responsibility away from the clinician or enrolled practice submitting the claim.

Sales compensation deserves similar scrutiny because commissions tied directly to the value or volume of federal program business can create substantial Anti-Kickback Statute risk, particularly when representatives recruit providers by emphasizing predictable profits rather than patient suitability or clinical performance.

Compliance teams should preserve contracts, pricing schedules, rebate calculations, claim-support communications, training materials, product shipment records, and internal approvals, because contemporaneous evidence can demonstrate either a carefully managed lawful program or unresolved warning signs ignored during rapid growth.

Executives who discover questionable arrangements should involve qualified health care counsel promptly, protect relevant records, stop potentially improper payments when appropriate, assess repayment and disclosure obligations, and avoid informal explanations that could later appear inconsistent with the company’s documented financial practices.

Patients and Taxpayers Behind the Billing Figures

Although the indictment is dominated by financial allegations, federal wound-care programs exist to support beneficiaries with serious medical needs, and improper incentives can distort treatment choices even when a product is real and some patients may receive genuine clinical benefit.

Taxpayers also carry the consequences because exceptionally high reimbursements can increase public spending, intensify scrutiny of legitimate providers, encourage restrictive payment responses, and redirect enforcement resources that could otherwise protect access to medically necessary care.

At the same time, fairness requires separating systemic concerns from individualized guilt, since neither the scale of a national takedown nor frustration over health care costs can substitute for admissible evidence proving McMillan knowingly joined the specific crimes charged.

Responsible reporting must therefore hold two ideas together: the allegations describe an exceptionally consequential distribution model deserving rigorous examination, while the constitutional process protects the accused until prosecutors prove their case through evidence tested in court.

Managing Public Scrutiny Without Obstructing Justice

An indictment of this magnitude can create immediate reputational damage for an executive, company, employee, provider, or commercial partner long before trial, making accurate timelines, preserved documentation, disciplined spokesperson procedures, and carefully reviewed public statements essential during the litigation.

Amicus International Consulting’s crisis public-relations guidance emphasizes structured assessment and consistent communication, while any response to a federal investigation must remain lawful, factually supportable, coordinated with defense counsel, and completely separate from witness influence, evidence concealment, or regulatory obstruction.

Its reputation rebuilding resources similarly focus on sustained credibility after damaging publicity, an approach that works best when corrections, updates, and explanatory material accurately distinguish allegations from adjudicated facts without attacking legitimate scrutiny or promising an outcome the evidence cannot support.

What Prosecutors Must Establish

To obtain a health care fraud conviction, prosecutors must prove more than a commercially successful distribution operation; they must show that McMillan knowingly and willfully participated in a deceptive scheme involving a health care benefit program and material falsehoods or fraudulent conduct.

For the kickback count, the government must establish the required connection between remuneration and federally reimbursable purchasing or ordering decisions, while persuading the fact-finder that challenged discounts or margins were intended as inducements rather than lawful price concessions.

The seven financial-transaction counts require additional tracing and knowledge evidence tied to particular transfers, meaning the government must demonstrate that the identified property exceeded the statutory threshold and came from qualifying criminal activity rather than merely moving through a business under investigation.

Witness credibility may become decisive if participating providers, former employees, representatives, or billing specialists cooperate, because jurors will need to assess whether their accounts are supported by contracts and messages or influenced by immunity, plea negotiations, financial exposure, and self-interest.

Prosecutors must also avoid treating every product delivered or every claim paid as interchangeable, while the defense can insist on claim-specific proof, complete financial context, accurate regulatory instructions, and a clear separation between disputed billing practices and intentional criminal deception.

The Defense Questions Likely to Shape the Case

McMillan’s attorneys can examine whether providers made independent clinical choices, whether Protectus relied upon outside compliance advice, whether invoices accurately represented enforceable obligations, and whether government billing instructions gave fair notice concerning discounts, rebates, and contingent payment terms.

They may also dispute the government’s loss calculation, argue that medically valuable products were actually supplied, challenge search or seizure evidence, contest expert methodologies, and seek exclusion of inflammatory lifestyle evidence whose emotional impact could exceed its relevance to charged intent.

None of those potential arguments guarantees dismissal or acquittal, just as a large indictment does not guarantee conviction, because the outcome will depend upon discovery, motions, witness examinations, expert analysis, judicial rulings, negotiations, and potentially a jury’s assessment.

The case will now move through arraignment and pretrial proceedings, where both sides can test the evidence, litigate the status of restrained assets, clarify the applicable reimbursement rules, and determine whether the dispute proceeds toward trial or a negotiated resolution.

No publicly announced schedule can reliably predict that conclusion, particularly in a document-intensive prosecution involving years of claims, multiple government programs, numerous providers, extensive financial records, complex medical products, and potentially contested expert testimony from several specialized fields.

A Broader Warning from the McMillan Prosecution

The prosecution’s larger message is that federal investigators are increasingly tracing health care money upstream, examining not only who treated and billed a patient but also who designed the incentives, recruited the providers, supplied the product, supported the claims, and divided the reimbursement.

For the wound-care industry, the dividing line will rarely be the label placed on an agreement, because regulators and juries can examine whether a supposed discount operated in practice as a reward for generating federally funded orders with unusually limited commercial risk.

For Michael McMillan, however, that industry warning remains separate from legal guilt, and every allegation concerning Protectus, provider payments, sales commissions, claim accuracy, criminal proceeds, and seized property must still survive adversarial testing under the demanding beyond-a-reasonable-doubt standard.

Until that process concludes, the case stands as both a prominent expansion of the 2026 National Health Care Fraud Takedown and an unresolved federal prosecution in which enormous financial figures cannot replace the evidence, legal instructions, and fair deliberation required for judgment.